Fed-batch methods for producing adalimumab
US-9234032-B2 · Jan 12, 2016 · US
Modified serum-free cell culture medium
US10119118B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10119118-B2 |
| Application number | US-201615187425-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 20, 2016 |
| Priority date | Sep 13, 2006 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
First claim
Opening claim text (preview).
What is claimed: 1. A serum-free cell culture medium comprising Part A, Part B, and Part C, wherein a) Part A consists essentially of a modified basal medium, wherein the modified basal medium is JRH 67411; b) Part B consists essentially of an inorganic iron source; and c) Part C comprises a recombinant growth factor; a buffer; and osmolarity regulator; an energy source; and at least two different non-animal hydrolysates.
Assignees
Inventors
Classifications
against hormone receptors (for antibodies against neuromediator receptors C07K16/286) · CPC title
from plants · CPC title
Cells for large scale production · CPC title
Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies · CPC title
Amino acids · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10119118B2 cover?
- The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
- Who is the assignee on this patent?
- Abbvie Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0037. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).